SELLAS Life Sciences Group, Inc. SLS
9.14 USD +0.27 (+3.04%)
At closeNov 4, 2026, 5:42 PM EST
9.17 +0.03 +0.33%
After hours · Nov 4, 5:42 PM ET
8.63 Day range 9.17
1.39 52-week range 15.88
- YTD
- +142.44%
- 1 year
- +450.60%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.50 +255.6% upside
Now 9.14
- Target (low)
- 30.00
- Target (mean)
- 32.50
- Target (high)
- 35.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.05 – -0.05 | -0.06 | +16.7% | 0 | 0.0% | 1 |
| Next quarter | -0.05 | -0.05 – -0.05 | -0.05 | 0.0% | 0 | 0.0% | 1 |
| Current year | -0.20 | -0.20 – -0.20 | -0.25 | +20.0% | 0 | 0.0% | 1 |
| Next year | -0.10 | -0.20 – 0.00 | -0.20 | +50.0% | 53.09M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | Maintained | Buy | Buy |
| Jul 16, 2025 | Maxim Group | Maintained | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | Maintained | — | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | Maintained | — | Overweight |
| Jul 21, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 15, 2019 | Maxim Group | Upgrade | Hold | Buy |
| Apr 8, 2019 | Alliance Global Partners | Initiated | — | Buy |
| Nov 1, 2018 | Oppenheimer | Initiated | — | Outperform |
| Jul 20, 2018 | Maxim Group | Maintained | Buy | Buy |
| Apr 2, 2018 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 19, 2018 | Maxim Group | Upgrade | Hold | Buy |